Clinical trials of new biologics in patients with inflammatory bowel disease (IBD), such as upadacitinib (Rinvoq), have shown promising results, with remission rates ...
Upadacitinib (UPA; Rinvoq) is an oral selective inhibitor for Janus kinase 1 approved for the treatment of tumor necrosis factor (TNF)-alpha-experienced patients with inflammatory bowel disease (IBD).
Inflammatory bowel disease (IBD) is a chronic condition with significant health implications worldwide. In Nigeria, data on its prevalence and characteristics are limited, highlighting the need for ...
Infectious colitis is an inflammatory condition caused by bacteria, a virus, or a parasite. It can cause diarrhea and other symptoms. Treatment will depend on the cause. Infectious colitis causes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results